Nurix Therapeutics, Inc. NRIX
25.82 USD +0.12 (+0.47%)
At closeNov 3, 2026, 6:31 PM EST
17.00 -8.82 -34.16%
After hours · Nov 3, 6:31 PM ET
25.63 Day range 26.53
11.67 52-week range 28.23
- YTD
- +36.11%
- 1 year
- +104.60%
Financial health
Altman Z-Score
9.10 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
7 / 9 Strong
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A-4 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 4
- P/E 3
- P/B 2
Valuation
P/E -5.5×
FY 2018 5y median -5.5× FY 2025
P/S 17.5×
FY 2018 5y median 17.5× FY 2025
P/B 2.7×
FY 2018 5y median 2.7× FY 2025
P/FCF -5.6×
FY 2018 5y median -5.6× FY 2025
EV/EBITDA -5.2×
FY 2018 5y median -5.2× FY 2025
EV/Sales 15.2×
FY 2018 5y median 15.2× FY 2025
FCF Yield -18.0%
FY 2018 5y median -18.0% FY 2025
Profitability
Gross Margin 77.5%
FY 2018 5y median -291.4% FY 2025
Operating Margin -340.2%
FY 2018 5y median -390.5% FY 2025
Net Margin -314.9%
FY 2018 5y median -354.9% FY 2025
ROE -49.1%
FY 2018 5y median -49.1% FY 2025
ROIC -47.3%
FY 2018 5y median -47.3% FY 2025
ROA -38.4%
FY 2018 5y median -38.4% FY 2025
Growth (YoY)
Revenue 54.0%
FY 2018 FY 2025
Operating Income -34.1%
FY 2018 FY 2025
EPS (diluted) -5.9%
FY 2018 FY 2025
Free Cash Flow -44.9%
FY 2018 FY 2025
Financial Health
Current Ratio 7.0×
FY 2018 5y median 4.7× FY 2025
Quick Ratio 7.0×
FY 2018 5y median 4.7× FY 2025
Debt / Equity 0.1×
FY 2018 5y median 0.1× FY 2025
Net Debt / EBITDA 0.8×
FY 2018 5y median 0.5× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-11-30
